Calcium channel blocker beta blocke...

Calcium channel blocker beta blocker and nitrates are commonly used to relieve chronic angina, a condition that affects at least 66 million somebodys in the United States. Patients ofttimes receive incomplete relief of symptoms with these mix with drugss Ranolazine may have anti-ischemic imports that could provide complementary or additive benefit to existing treatment regimens. The Monotherapy Assessment of Ranolazine In Stable Angina (MARISA) trial demonstrated that ranolazine, taken twice a day, increases exercise tolerance and affords longer exercise duration before the appearance of anginal symptoms and ST-segment depression. Chaitman and colleagues report upon the Combination Assessment of Ranolazine In Stable Angina (CARISA) trial, which assessed anginal symptoms in patients with chronic angina and accurate coronary disease whose angina was inadequately controll with atenolol, diltiazem, or amlodipine.

In this randomized, double-blind trial, three assemblages of subjects were assigned to receive twice-daily placebo, or common of two dosages of sustained-release ranolazine for 12 weeks. The study's primary completion point was to compare the consequences of ranolazine with placebo onward treadmill exercise duration at furrow ranolazine levels (i.e., 12 hours after dosing). extremity points also included exercise duration at peak mix with drugs levels (four hours after dosing), times to angina and to 1-mm ST-segment depression at peak and wooden channel levels, and reported angina attacks and sublingual nitroglycerin uses.

At enrollment 354 (43 percent) of the 823 randomized patients were taking atenolol, 256 (311 percent) were taking amlodipine, and 213 (259 percent) were taking diltiazem. Patients were randomized to receive placebo, or 750 or 1000 mg of ranolazine.

Exercise duration in those taking ranolazine was increased compared with those taking placebo. Each ranolazine dose increased treadmill exercise duration at as well-as; not only-but also; not only-but; not alone-but trough and peak levels; this meaning was sustained throughout the duration of the trial at as well-as; not only-but also; not only-but; not alone-but dosage levels. Similar effects were observ for times to angina and ischemia, as noted upon electrocardiograph tracings. These effects, which were generally greater at peak ranolazine flats did not differ substantially by way of background antianginal medication group. Ranolazine reduc the mean number of weekly angina attacks from 33 in the placebo clump to 2.5 and 2.1 in the 750 and 1000 mg ranolazine form into groupss respectively.

Even with revascularization manner of proceedings to relieve angina, about single fourth of participants still had attacks. The addition of ranolazine to standard antianginal medication appears to render angina frequency and nitroglycerin consumption. Exercise duration increased by means of 115.6 seconds in patients taking ranolazine compared with 917 next to the firsts in those taking placebo. Adverse side weights included constipation, nausea, asthenia, and dizziness in 62 percent more patients than those taking placebo.

The authors bring to an end that ranolazine increases exercise capacity and provides additional antianginal relief in symptomatic patients with bitter chronic angina and is well tolerated.

CAROLINE WELLBERY, MD Chaitman BR et al. purports of ranolazine with atenolol, amlodipine, or diltiazem upon exercise tolerance and angina oftenness in patients with severe chronic angina. A randomized controll trial. JAMA January 21 2004;291:309-16

COPYRIGHT 2004 American Academy of Family Physicians

COPYRIGHT 2004 Gale Group